We report the clinical case of an atopic patient with important manifestations impacting the quality of life at the cutaneous and ocular site. The condition resisted conventional treatments, and omalizumab had to be used to treat the disease successfully.

Zengarini C., Roda M., Schiavi C., Bruni F., Bardazzi F., Bellusci C., et al. (2021). Successful treatment of severe recalcitrant vernal keratoconjunctivitis and atopic dermatitis associated with elevated IgE levels with omalizumab. CLINICAL AND EXPERIMENTAL DERMATOLOGY, Clin Exp Dermatol . 2021 Nov 3. doi: 10.1111/ced.15000. Online ahead of print., 1-2 [10.1111/ced.15000].

Successful treatment of severe recalcitrant vernal keratoconjunctivitis and atopic dermatitis associated with elevated IgE levels with omalizumab

Zengarini C.
Primo
Writing – Original Draft Preparation
;
Roda M.
Secondo
Investigation
;
Schiavi C.
Conceptualization
;
Bruni F.
Investigation
;
Bellusci C.
Penultimo
Investigation
;
Raone B.
Ultimo
Supervision
2021

Abstract

We report the clinical case of an atopic patient with important manifestations impacting the quality of life at the cutaneous and ocular site. The condition resisted conventional treatments, and omalizumab had to be used to treat the disease successfully.
2021
Zengarini C., Roda M., Schiavi C., Bruni F., Bardazzi F., Bellusci C., et al. (2021). Successful treatment of severe recalcitrant vernal keratoconjunctivitis and atopic dermatitis associated with elevated IgE levels with omalizumab. CLINICAL AND EXPERIMENTAL DERMATOLOGY, Clin Exp Dermatol . 2021 Nov 3. doi: 10.1111/ced.15000. Online ahead of print., 1-2 [10.1111/ced.15000].
Zengarini C.; Roda M.; Schiavi C.; Bruni F.; Bardazzi F.; Bellusci C.; Raone B.
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/857390
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 5
social impact